|Articles|March 28, 2011

HIT Press Club AJMC - Katlyn Nemani, BA

Katlyn Nemani, BA, Tufts University School of Medicine, discusses her paper

Katlyn Nemani, BA, Tufts University School of Medicine, discusses her paper and answers questions at the Healthcare Innovations and HIT Q&A Session at the National Press Club in Washington, DC

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Trending on AJMC

HIT Press Club AJMC - Katlyn Nemani, BA

Related Content

Specialty Pharmacy Drives Advanced Therapy Access: Fran Gregory, PharmD

Teclistamab Outperforms Len/Dex in High-Risk Smoldering Myeloma With Higher CR Rate, PFS: Omar Nadeem, MD

SENTRY Trial Shows Survival, Spleen Benefits in Myelofibrosis: Claire Harrison, MD

Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD

Blinatumomab Improves Outcomes, Toxicity in High-Risk Pediatric ALL: Martin Schrappe, MD, PhD

Trending on AJMC

EHA 2026 Late Breakers Deliver Practice-Shifting Phase 3 Data and Novel CAR T Approaches Across Hematology

MRD-Guided CLL Treatment Duration: Personalization or Malpractice?

Paul Richardson, MD, Calls Mezigdomide “CAR T in a Pill” for Patients With R/R Multiple Myeloma

SENTRY Trial Shows Survival, Spleen Benefits in Myelofibrosis: Claire Harrison, MD

Teclistamab Outperforms Len/Dex in High-Risk Smoldering Myeloma With Higher CR Rate, PFS: Omar Nadeem, MD